OSE ImmunotherapeuticsORPOF 41 PB Ratio is 3.06 as of Jun. 27, 2026, which is 49% above its 10-year median of 2.06. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $3.36 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,232 Biotechnology companies, OSE Immunotherapeutics ranks better than 50.97% on this metric.
The historical rank and industry rank for OSE Immunotherapeutics's PB Ratio or its related term are showing as below:
ORPOF'
s PB Ratio Range Over the Past 10 Years
Min: 0.77 Med: 2.06 Max: 9.62
Current: 2.82
During the past 13 years, OSE Immunotherapeutics's highest PB Ratio was 9.62. The lowest was 0.77. And the median was 2.06.
ORPOF's PB Ratio is ranked better than 50.97% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ORPOF: 2.82
During the past 12 months, OSE Immunotherapeutics's average Book Value Per Share Growth Rate was -57.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -13.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -7.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of OSE Immunotherapeutics was 42.50% per year. The lowest was -32.20% per year. And the median was -7.85% per year.
Back to Basics: PB Ratio
OSE Immunotherapeutics (OTCPK:ORPOF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OSE Immunotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OSE Immunotherapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where OSE Immunotherapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
OSE Immunotherapeutics (ORPOF) has a PB Ratio of 3.06 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OSE Immunotherapeutics and its competitors. This is 49% above median its historical median of 2.06. Over the past decade, OSE Immunotherapeutics' PB Ratio has ranged from 0.77 to 9.62. According to the industry distribution chart, OSE Immunotherapeutics ranks #604 out of 1232 companies in the Biotechnology industry, placing it in the top 49%.
Is OSE Immunotherapeutics' PB Ratio too high?
OSE Immunotherapeutics' current PB Ratio of 3.06 is 49% above median its 10-year median of 2.06. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 9.62. The Biotechnology industry median PB Ratio is 2.80. OSE Immunotherapeutics' value of 3.06 is 9.3% above this industry median. Based on the distribution chart, OSE Immunotherapeutics ranks #604 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #604 out of 1232 companies for PB Ratio. This puts OSE Immunotherapeutics in the upper half of its industry. The industry median PB Ratio is 2.80. OSE Immunotherapeutics' value of 3.06 is 9.3% above this benchmark. Historically, OSE Immunotherapeutics' own PB Ratio has ranged from 0.77 to 9.62 over the past decade. While the company's 10-year median is 2.06 vs. the industry median of 2.80, OSE Immunotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OSE Immunotherapeutics's current PB Ratio of 3.06 is 9.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OSE Immunotherapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OSE Immunotherapeutics's current PB Ratio is 3.06, which is 49% above median its own 10-year median of 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.36, compared to a current price of $4.43 — trading 31.8% above its estimated fair value. The current PB Ratio is 3.06, which is 49% above median its 10-year median of 2.06 and 9.3% above the Biotechnology industry median of 2.80. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current PB Ratio is 3.06 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?
Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued.
The current stock price of $4.43 is trading 31.8% above its estimated GF Value™ of $3.36.
GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.
Key valuation signals for ORPOF:
PB Ratio: 3.06 (49% above median its 10-year median of 2.06)
GF Value™: $3.36 vs. price of $4.43 (31.8% above fair value)
Industry Position: 9.3% above the Biotechnology median (#604 of 1232)
No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score
Get the complete analysis for ORPOF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPOF has been successfully added to your 
